Xeltis is committed to improving the quality of life of patients requiring vascular surgery, such as those in need of hemodialysis vascular access.
These patients, who already face considerable health challenges, struggle with continuous surgical interventions, which can place significant additional burden on them and their families.
The current standard-of-care for vascular surgery is based on materials that have been in use for decades with limited innovation.
Physicians have a choice between animal-derived or synthetic materials which are associated with high rates of rejection, are prone to infection and require additional interventions to maintain their short life span.
Xeltis’ ongoing clinical programs are seeking to address these significant challenges, and offer transformative implants with reduced rates of infection, rejection and need for reintervention.
CLINICAL TRIALS
aXess EU Pivotal Trial 2023
AV Hemodialysis Access Conduit
The aXess pivotal clinical trial is an ongoing study in Europe evaluating the performance and safety of the device in patients with end-stage kidney disease requiring hemodialysis. Patient enrollment has been completed, and the study successfully met its primary endpoints.
Visit Website
Watch our film on the ongoing aXess EU Pivotal Trial
aXess Pivotal US Clinical Trial
AV Hemodialysis Access Conduit
The aXess pivotal clinical trial is an ongoing study in the US evaluating the performance and safety of the device in patients with end-stage kidney disease requiring hemodialysis. Patient enrollment is ongoing.
Visit Website
aXess EU FIH Study
AV Hemodialysis Access Conduit
A feasibility study to assess the preliminary safety and performance of the Xeltis hemodialysis vascular access conduit (aXess).
Visit Website
XABG/CABG
Coronary Artery Bypass Conduit
Prospective, non-randomized, first in human (FIH) clinical study to assess the feasibility of the novel Xeltis coronary artery bypass conduit (XABG)
Visit Website
Xplore-2
Pulmonary Heart Valve Replacement
The Xplore-2 clinical trial is an ongoing study conducted in Europe and the US to investigate evaluating the safety and perfomance of the Xeltis pulmonary valved conduit in patients with congenital heart-failure.
Visit Website
Xeltis is a medtech company developing transformative vascular implants that enable the natural creation of living and long-lasting tissue.
Visit our About page to learn more.
About